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Recognizing Miller Fisher Syndrome
Samer Bolis DO and Stacey Smith MD

Lehigh Valley Health Network, Allentown, Pennsylvania

Case

Abstract
• In a case of Miller Fisher Syndrome (MFS) with an atypical presentation of
internuclear opthalmoplegia (INO), a convergence deficit was present without
discernable pathology on brain MRI to suggest central nervous system lesions
• This unusual presentation may indicate that severe peripheral nerve conduction
defects may manifest as pseudo-internuclear opthalmoplegia rather than true
INO (Image 1)
• This case suggests that CNS involvement and INO may be overdiagnosed in
atypical cases of MFS

Image 1: True INO

Introduction
• G
 uillain-Barré syndrome (GBS), once considered a single disorder, is now recognized as a spectrum of
distinguished variants. Miller Fisher syndrome (MFS) comprises 1 - 5% of GBS cases in the US and 25%
of cases in Japan
• Pathophysiology involves antigenic mimicry typically following exposure to infectious agents, resulting
in an autoimmune response targeting peripheral nerve myelin (GM1,GD1 ganglosides of spinal nerves &
GQ1b gangliosides of cranial nerves)
• Median age at onset is 40 (range 13 – 78 years). A consistent male predominance of 2:1 is typically noted
• Median onset of neurologic symptoms after infection is 8 days (range 1- 30 days)
• There are many variations for the pattern in which conduction defects present (Table 1)

− Typically, initial symptoms include diplopia and ataxia, which progress to opthalmoplegia and areflexia by
week 1 of clinical presentation

− By week 2 and 3, 60% and 92% respectively will reach a nadir in symptoms, and by definition all symptoms
must peak at week 4 followed by a plateau period before improvement

− Clinical manifestations are often self limited and complete resolution of less severe cases occurs over weeks
to months

• C
 SF analysis reveals normal pressure and cell counts with an albuminocytologic dissociation after 48 hrs
of symptom onset
• Nerve conduction studies and electromyography often demonstrate evolving multifocal demyelination,
i.e., slowed conduction velocity, motor conduction blockade,
Table 1. Frequencies of Presenting Symptoms
prolonged distal latencies
Symptoms
% of Cases
• MRI is sensitive but not specific, often showing nerve root
100
Opthalmoplegia, Ataxia, Areflexia
enhancement

− Cauda equina nerve roots are affected in 83% of patients
with GBS and MFS

• IgG antibodies to GQ1b has sensitivity and specificity
of 90% in diagnosing MFS and Bickerstaff’s brainstem
encephalopathy (BBE), a rare variant of GBS
• Plasmapheresis is the definitive therapy in severe cases of
MFS compromise and decreasing vital capacity.

− Treatment of choice for patients who progress to a

prolonged course of illness, longer than 4-8 weeks, or those
with cardiopulmonary compromise and decreasing vital
capacity

Diplopia

80

Headache

45

Ptosis

27.3

Nausea and Vomiting

25

Lower Limb Weakness

20

Upper Limb Weakness

16

General Weakness

8

Micturition Disturbance

3

Babinski Reflex

<1

Decreased Vibratory Sensation

<1

Internuclear Opthalmoplegia

<1

References:
1. A jena D, Ferrari S, Romito S, Zaglia F, Biban P, Squintani G. A pediatric case of Miller Fisher syndrome with central involvement. Neurol Sci. 2013;34(9):1689-90.
2. Yeh JH, Chen WH, Chen JR, Chiu HC. Miller Fisher syndrome with central involvement: successful treatment with plasmapheresis. Ther Apher. 1999;3(1):69-71.
3. Inoue N, Ichimura H, Goto S, Hashimoto Y, Ushio Y. MR imaging findings of spinal posterior column involvement in a case of Miller Fisher syndrome. AJNR Am J
Neuroradiol. 2004;25(4):645-8.
4. Lo YL, Ratnagopal P. Transcranial magnetic stimulation studies in the Miller Fisher syndrome: evidence of corticospinal tract abnormality. J Neurol Neurosurg
Psychiatr. 2001;71(2):210-4.
5. Kim YK, Kim JS, Jeong SH, Park KS, Kim SE, Park SH. Cerebral glucose metabolism in Fisher syndrome. J Neurol Neurosurg Psychiatr. 2009;80(5):512-7.
6. Phillips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatr. 1984;47(5):492-5.
7. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff’s brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol.
2008;255(5):674-82.
8. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56(8):1104-6.
9. Izadi S, Sabzgolin I. A case of Guillain-Barre syndrome presenting with bilateral pseudo-internuclear ophthalmoplegia. Neurol. 2015; 6(2): 33-5.
10. Poonyathalang A, Khanna S, Leigh RJ. A reinterpretation of certain disorders affecting the eye muscles and their tissues. Clin Ophthalmol. 2007;1(4):415-20.
11. Thompson J, Spies J, Jankelowitz S. Phenotypic variation in Miller Fisher syndrome. Clin Neuro. 2014; 21(11): 2051-5.
12. Yuan CL, Wang YJ, Tsai CP. Miller fisher syndrome: a hospital-based retrospective study. Eur Neurol. 2000;44(2):79-85.

• A 53 year old male presented with a new onset of diplopia and headache after having URI symptoms two
weeks prior
• On day 2 of presentation, exam revealed bilateral internuclear opthalmoplegia (INO), with nystagmus and
mild skew deviation of the abducting eye
• Pupils became unreactive and dilated, with a convergence dysfunction as ataxia developed on day 3 with a
worsening unsteady gate. Initial head CT and MRI of the brain were nonspecific.
• By day four, the patient had developed complete areflexia of upper and lower extremities
• An LP showed elevated CSF protein
• A nerve conduction study revealed symmetrically diminished sensory and motor nerve peaks of both upper
and lower extremities, compatible with the clinical suspicion of MFS
• The patient also tested positive for antibodies against GQ1b, a component of ganglioside in nerve tissue
• Treatment with plasmapheresis was undertaken and the patient progressively improved on physical exams.  

Discussion
Central nervous system involvement in Miller Fisher Syndrome is often debated with inconsistent supportive
findings throughout published literature. Multiple case studies have reported possible brainstem and spinal
cord involvement based solely on symptomology and physical exams without evidence of cerebral CT or MRI
1,2
changes.
One case study found posterior column lesions on MRI 5 months after immunotherapy and complete symptom
3
resolution. Few patients have been evaluated using transcranial magnetic stimulation to suggest conduction
delay in MFS4 whereas cerebral glucose nuclear scans showed generalized hypermetabolism without
describing focal lesions.5
Postmortem examinations of MFS patients failed to reveal central demyelination, often finding incidental
histopathologic abnormalities of the CNS in the background of diffuse peripheral nerve root lesions. Such CNS
6,7
findings were thought to be infiltrative postmortem changes rather than true demyelination.
Ito, et al. analyzed 581 patients with either Bickerstaff’s brainstem encephalitis or Miller Fisher syndrome. Their
findings suggest that GBS, MFS, and BBE all form a continuous spectrum with overlapping characteristics and
variable CNS and PNS involvement. BBE was however noted more frequently on MRI and postmortem exams
than MFS. No MRI lesions were noted in the CNS of this study’s MFS patients who displayed INO and other CNS
findings like Babinski sign.7
Out of 50 confirmed MFS patients evaluated by Mori, et al., one was reported to have internuclear
8
opthalmoplegia on exam.  This was speculated as being a CNS lesion, however, there was no further workup.
Internuclear ophthalmoplegia is characterized by impaired adduction of the affected eye, and abduction
nystagmus of the contralateral eye. It is a specific finding in Multiple sclerosis. Unilateral and bilateral
internuclear opthalmoplegia have been described in cases of Miller Fisher syndrome. Pseudo-internuclear
opthalmoplegia is associated with Myesthenia gravis and indicative of severe peripheral neuromuscular
blockade. It is believed that the CNS causes hypermetria in an attempt to overcompensate for the peripheral
weakness, leading to oscillations and saccadic eye movements mimicking INO. This has been described in
several cases of GBS and MFS.9, 10
Given the absence of lesions on MRI and the convergence deficits noted in our subject, it is possible to
conclude that our patient displayed Pseudo-INO, which may be confused with internuclear opthalmoplegia.

Conclusion
• Given the scarcity of evidence to support CNS involvement, it is difficult to definitively conclude whether MFS
is exclusively a peripheral or central nervous system process. There is however adequate support to suggest
that GBS, MFS, and BBE are all components of the same spectrum. Overlapping characteristics of BBE and
MFS may very well create confounding results and raise the question as to whether MFS is accurately being
1
diagnosed.1 Without tangible evidence of internuclear opthaloplegia in MFS, this atypical presentation can
be regarded as CNS overcompensation for severe peripheral nerve weakness.
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